AOD-9604
Anti-Obesity Drug 9604 — HGH Fragment 176-191
What is AOD-9604?
AOD-9604 is a synthetic fragment of human growth hormone (amino acids 176-191) that passed Phase 2 clinical trials for obesity before the NDA was withdrawn for commercial rather than safety reasons. It retains the fat-metabolizing properties of HGH without IGF-1 stimulation or blood glucose effects.
AOD-9604 directly activates fat cell receptors to stimulate lipolysis and inhibit lipogenesis. Unlike full HGH, it does not raise IGF-1, does not affect blood glucose, and does not produce anabolic effects — making it a targeted fat oxidation agent without HGH systemic effects.
Research Evidence
Animal studies consistently demonstrate dose-dependent reduction in body fat mass and increased lipolysis without affecting lean mass or glucose metabolism.
Phase 1 and 2 clinical trials established a strong safety profile. Efficacy results in humans were modest and inconsistent across trials.
Community protocols stack AOD-9604 with GLP-1 agonists to preferentially target fat stores during caloric restriction. No controlled trials for this combination.
Evidence grades: Gold = RCT human data · Silver = multiple animal studies, consistent · Bronze = limited or preliminary
Dosing Protocols
Reconstitution Guide
| Vial Size | BAC Water | Concentration | Target draw |
|---|---|---|---|
| 2 mg | 2 ml | 1 mg/ml | 250mcg = 25 units |
| 5 mg | 4 ml | 1.25 mg/ml | 250mcg = 20 units |
Frequently Asked Questions
Does AOD-9604 affect blood sugar?
No. Unlike full HGH, AOD-9604 does not stimulate IGF-1 or affect insulin sensitivity. This is one of its key advantages — fat oxidation without metabolic disruption.
Is AOD-9604 the same as HGH?
No. AOD-9604 is a fragment of HGH (amino acids 176-191). It retains fat metabolism properties without anabolic effects, IGF-1 stimulation, or blood sugar impacts.
References
- [1]Heffernan MA, Thorburn AW, Fam B, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone fragment 176-191. Int J Obes Relat Metab Disord. 2001;25(10):1442-1449.
This profile was prepared using AI-assisted research synthesis. Citations are provided where applicable — verify with primary sources before clinical application.
Share this article